Benitec Biopharma Inc. 8-K

What Happened

• On February 12, 2026, Benitec Biopharma Inc. announced its financial results and provided an operational update for the fiscal quarter ended December 31, 2025. The announcement was issued via a press release that the company furnished as Exhibit 99.1 to a Current Report on Form 8-K (Item 2.02: Results of Operations and Financial Condition). The filing was signed by CEO Dr. Jerel A. Banks.

Key Details

• Filing date: February 12, 2026 (Form 8-K, Item 2.02).
• Reporting period: fiscal quarter ended December 31, 2025.
• Disclosure method: press release furnished as Exhibit 99.1 to the 8-K.
• Authorized signer: Dr. Jerel A. Banks, Chief Executive Officer.

Why It Matters

• This 8-K notifies investors that Benitec has released its latest quarterly earnings and operations update—key information for assessing recent performance (revenues, expenses, cash position, program progress).
• The Form 8-K furnishes the press release rather than embedding detailed financial statements in the filing text; investors should read Exhibit 99.1 and any accompanying SEC filings (e.g., Form 10-Q) for the full financial figures and management commentary.
• Reviewing the press release will help shareholders and prospective investors evaluate near-term funding needs, clinical or program milestones, and any changes in financial condition or guidance disclosed for the quarter.